

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau




(43) International Publication Date  
24 June 2004 (24.06.2004)

PCT

(10) International Publication Number  
WO 2004/053052 A2

- (51) International Patent Classification<sup>7</sup>: C12N
- (21) International Application Number: PCT/BR2003/000189
- (22) International Filing Date: 8 December 2003 (08.12.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
PI0205000-5 9 December 2002 (09.12.2002) BR  
PROVISIONAL 012478  
5 December 2003 (05.12.2003) BR
- (71) Applicant and  
(72) Inventor: CAMARGO, Antônio [BR/BR]; 55 Mario Fer-  
raz St., RM 11, Jardim Europa, 01453-010 São Paulo (BR).
- (72) Inventors; and  
(75) Inventors/Applicants (for US only): HAYASHI, Mirian [BR/BR]; 159 Alameda Fernão Cardim, RM 101, Jardins,  
01403-020 São Paulo (BR). PORTARO, Fernanda [BR/BR]; 91 Paulo Ribeiro da Luz St., 05599-140 São  
Paulo (BR). GUERREIRO, Juliano [BR/BR]; 67 Paulina  
Gobeth Camargo, Cecap II, 13421-470 Piracicaba (BR).
- (74) Agent: LLC INFO CONNECTION LTDA.; 5555 Dom  
Hélder Câmara Av., RM 312, Pilares, 20771-001 Rio de  
Janeiro (BR).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,  
CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,  
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,  
SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (BW, GH,  
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,  
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,  
GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— without international search report and to be republished  
upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROCESS FOR THE DETERMINATION OF THE PRIMARY STRUCTURE OF THE MESSENGER RNA CODING  
FOR THE HUMAN RECOMBINANT ENDOOLIGOPEPTIDASE A (hEOPA) [AF217798]...



```

312  TAGTACAGGC  GAATTCCAG  GAAAGGAGCA  GAGAATTAGA  AGCAGAGTTG  GAGGCACAAAT
361  TGACRCAARGA  ARTAGAGACT  TGCAGGCTGA  TAACCAAAGA  CTGAARTATG
421  ARGGCGAGGC  ATTAAGGAG  ARGGCTAGAGC  ATCRATATGC  ACAGAGCTAT  AAGCAGGTCT
481  CAGTGTAGA  AGATGATTAA  ACTCAGACTC  GGGCCATTA  GGACCGTTG  CATAAGTATG
541  TGAGACAGCT  CGAGCAGGCC  AACGACGAC  TGGAGCGAGC  CAAAGGGCA  ACAATAGTTT
601  CACTGGAAAGA  CTTTCRACAA  AGGCTTAAAC  AGGCCCATG  AGCAAAATGCA  TTTTTAGAAA
661  GTGACRCTTGA  TGAARRGGAA  TCTTTGTTGG  TCTCTGACR  GAGGTTAAAG  GATGARGCAA
721  GAGATTTAAC  GCAAGAAACTA  GCAGTTCGGG  ARAAGACRCA  GGAGRTAACT  AGAARAGTCGG
781  CTCCTAGCTC  TCCARCTCTA  SACTGTTGAAA  AGATGGACTC  CGCCGTAACAA  GCACTACATT
841  CTTTGCCAGC  TACCCCTGTT  CCCARRGAA  CGGAGRACAC  TTTTCCCTCA  CGGARAGCTA
901  TACCAAATGG  TTTGGTACCC

```

(57) Abstract: This invention refers to the recombinant human endooligopeptidase (hEOPA), polynucleotide which codes for the hEOPA, polynucleotide which allow the expression of the EOPA in prokaryotes and eukaryotes, including the human beings; use of the synthetic substrates for the determination of the proteolytic activity of the hEOPA, or of its chaperon activity or its activity as soluble peptide receptor; obtaining and using of the specific antibodies and inhibitors of its oligopeptide binding activity, as agonists, competitors and antagonists, which are able to disturb its interaction and the complex formation with other proteins. The invention also refers to the application of the natural and recombinant protein, chemically or genetically modified which aim is the diagnosis and/or the application in congenital, infectious and degenerative pathologic conditions of the central nervous system, and for psychiatric and behavioral dysfunctions. It is also proposed the application of the inhibitors and competitors for the interaction of EOPA with ligands, including antibodies or their derivatives, for the treatment of tissular and neurodegenerative pathologies.